Percutaneous Coronary Intervention

The 2020 European Society of Cardiology guidelines for the management of non ST-elevation ACS may help clinicians determine the thrombotic risk categories of patients being considered for PCI, a speaker reported.

Ticagrelor monotherapy after 3-month dual antiplatelet therapy was not associated with greater risk for repeat revascularization or MACCE at 1 year after PCI vs. continued DAPT, a speaker reported.

Distal radial artery access for PCI showed no significant change in hand function and similar rates of access-site bleeding and radial artery occlusion at 1 year vs. proximal access, a speaker reported.

A drug-eluting coronary implant adaptable to vessel physiology with uncaging elements was safe and effective compared with a contemporary drug-eluting stent, demonstrating superior restoration of vessel motion and function, data show.

Comparing clinical outcomes between intravascular imaging-guided vs. angiography-guided PCI in complex lesions.

Comparing single antiplatelet therapy after 3-month DAPT with 12-month DAPT after PCI with third-generation DES with the thinnest struts.

A Clinton-era initiative to reduce racial/ethnic health disparities may have helped to minimize inequities in PCI usage and mortality after STEMI among Black, white and Hispanic patients in New Jersey, researchers reported.

In average-capacity markets, patients with acute MI were more likely to receive revascularization on the day of admission or during an in-hospital care episode and were less likely to die as more PCI centers opened, data show.

Patients hospitalized for acute MI with a high platelet-to-lymphocyte ratio are up to three times more likely to experience major adverse CV events in the 30 days after undergoing PCI, researchers reported.

Increased change in fractional flow reserve at 3-month follow-up after PCI was moderately associated with less angina and improved quality of life, researchers reported.